Visionary Holdings (NASDAQ:GV) filed its audited financial statements for the fiscal year ended March 31, 2025, revealing a significant revenue decline as the company transitions away from its legacy education and real estate businesses toward a high-margin health and anti-aging platform.
Bristol Myers Squibb (NYSE:BMY) has partnered with Microsoft (NASDAQ:MSFT) to deploy artificial intelligence tools aimed at identifying lung cancer in its earliest stages, marking the latest push by a pharmaceutical giant to integrate big tech’s machine learning into clinical care.
Corvus Pharmaceuticals (NASDAQ:CRVS) shares skyrocketed more than 60% in early trading Tuesday after the company reported that its experimental oral therapy significantly cleared skin in patients with moderate-to-severe atopic dermatitis.
Viatris (NASDAQ:VTRS) has officially commenced the global expansion of its cardiovascular portfolio with the launch of Inpefa (sotagliflozin) in the United Arab Emirates, marking the first commercial availability of the therapy outside the United States.
MAIA-BIOTECH-2026-CLINICAL-OUTLOOK
Phio Pharmaceuticals (NASDAQ:PHIO) reported that its experimental gene-silencing therapy cleared tumors in the majority of patients during a mid-stage study, marking a significant win for its proprietary INTASYL technology.
Regentis Biomaterials (NYSE:RGNT) shares gained after new long-term imaging data showed its hydrogel implant successfully regenerated knee cartilage with a structural complexity nearly identical to healthy human tissue.
Celcuity (NASDAQ:CELC) shares rose in premarket trading Tuesday after the U.S. Food and Drug Administration accepted the New Drug Application for gedatolisib, a potential first-in-class therapy for patients with advanced breast cancer.
Dyne Therapeutics (NASDAQ:DYN) secured a regulatory win in Asia as Japanese authorities granted orphan drug status to its lead candidate for myotonic dystrophy, providing the biotech with a clear path toward market exclusivity in the world’s third-largest pharmaceutical market.
Eli Lilly (NYSE:LLY) shares gained after the U.S. Food and Drug Administration granted Breakthrough Therapy designation to its experimental antibody-drug conjugate, potentially accelerating the path to market for a treatment targeting hard-to-treat gynecologic cancers.
Melbourne, Australia-based Telix Pharmaceuticals (NASDAQ:TLX) reported unaudited financial and operational highlights for the full year and fourth quarter ended December 31, 2025.
Novavax (NASDAQ:NVAX) shares rose in early trading after the company reached an agreement to license its vaccine-boosting technology to Pfizer (NYSE;PFE), providing a fresh source of capital for the Maryland-based biotech.
-1-640x358.jpg&w=3840&q=75)